Atlas Trials

Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

Clinical trial NCT06422143 · RECRUITING

Trial details

NCT number
NCT06422143
Sponsor
Merck Sharp & Dohme LLC
Status
RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Non-small Cell Lung CancerNSCLC
Start date
2024-06-10
Primary completion
2029-01-12
Enrollment
851

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.